{"title":"[Similar but not identical biosimilars: the vision of innovators].","authors":"Sabine Sydow, Karl-Heinz Grajer","doi":"10.1002/pauz.201200494","DOIUrl":"https://doi.org/10.1002/pauz.201200494","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"41 6","pages":"474-80"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pauz.201200494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31198235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Homöopathie für die junge Familie. Von Brigitte M. Gensthaler","authors":"Christian Redmann","doi":"10.1002/PAUZ.201290113","DOIUrl":"https://doi.org/10.1002/PAUZ.201290113","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"75 1","pages":"504-505"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85559388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[What is exactly alike? High-performance analytics for development of biosimilars].","authors":"Martin Blüggel","doi":"10.1002/pauz.201200493","DOIUrl":"https://doi.org/10.1002/pauz.201200493","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"41 6","pages":"468-73"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pauz.201200493","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31198234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Eine kurze Geschichte der Genetik. Von Rolf Knippers","authors":"Thomas Winckler","doi":"10.1002/PAUZ.201290108","DOIUrl":"https://doi.org/10.1002/PAUZ.201290108","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"72 1","pages":"503-503"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84104719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
2010 wurden in Deutschland 26 Arzneimittel mit neuen Wirkstoffen (international auch als NME – New Molecular Entity – bezeichnet) im Markt eingefuhrt. Bei den Ausgaben fur Arzneimittel liegt Deutschland mit einem Anteil von 15,1 % an den gesamten Gesundheitsausgaben (rund 280 Mrd. Euro) nach wie vor deutlich unter dem Niveau der meisten europaischen Lander und Japans. Die Ausgaben der GKV fur Arzneimittel betragen 32,0 Mrd. Euro oder 18 %. Von den Gesamtausgaben der GKV entfallen nur 4 % (6,7 Mrd. Euro) auf patentgeschutzte Arzneimittel.
{"title":"[Cost-effectiveness advantage? Pharmacoeconomic aspects of biosimilars].","authors":"Evelyn Walter","doi":"10.1002/pauz.201200496","DOIUrl":"https://doi.org/10.1002/pauz.201200496","url":null,"abstract":"2010 wurden in Deutschland 26 Arzneimittel mit neuen Wirkstoffen (international auch als NME – New Molecular Entity – bezeichnet) im Markt eingefuhrt. Bei den Ausgaben fur Arzneimittel liegt Deutschland mit einem Anteil von 15,1 % an den gesamten Gesundheitsausgaben (rund 280 Mrd. Euro) nach wie vor deutlich unter dem Niveau der meisten europaischen Lander und Japans. Die Ausgaben der GKV fur Arzneimittel betragen 32,0 Mrd. Euro oder 18 %. Von den Gesamtausgaben der GKV entfallen nur 4 % (6,7 Mrd. Euro) auf patentgeschutzte Arzneimittel.","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"41 6","pages":"485-91"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pauz.201200496","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31198237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Biosimilare Arzneimittel (Biosimilars) sind Nachfolgeprodukte biomedizinischer Arzneimittel, die ihren Patentschutz verloren haben. Im Gegensatz zu “klassischen” Generika werden fur Biosimilars in jedem Fall klinische Studien gefordert.
{"title":"[Comparison of generics and original biopharmaceutical drugs. The clinical development of biosimilars].","authors":"Carsten Brockmeyer","doi":"10.1002/pauz.201200492","DOIUrl":"https://doi.org/10.1002/pauz.201200492","url":null,"abstract":"Biosimilare Arzneimittel (Biosimilars) sind Nachfolgeprodukte biomedizinischer Arzneimittel, die ihren Patentschutz verloren haben. Im Gegensatz zu “klassischen” Generika werden fur Biosimilars in jedem Fall klinische Studien gefordert.","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"41 6","pages":"461-7"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pauz.201200492","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31198233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Editorial: Pharmazie in unserer Zeit 6/2012].","authors":"Theo Dingermann","doi":"10.1002/pauz.201290096","DOIUrl":"https://doi.org/10.1002/pauz.201290096","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"41 6","pages":"439"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pauz.201290096","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31023630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[When two do the same, it is not the same. Requirements for development and quality of biosimilars].","authors":"Isam Rais","doi":"10.1002/pauz.201200491","DOIUrl":"https://doi.org/10.1002/pauz.201200491","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"41 6","pages":"453-60"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pauz.201200491","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31198232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Dingermann, M. Schubert-Zsilavecz, D. Steinhilber, Klaus Mickus, Carol Bacchus
{"title":"DPhG Aktuell: Editorial","authors":"T. Dingermann, M. Schubert-Zsilavecz, D. Steinhilber, Klaus Mickus, Carol Bacchus","doi":"10.1002/PAUZ.201290104","DOIUrl":"https://doi.org/10.1002/PAUZ.201290104","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"42 1","pages":"494-494"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82333608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[White, brown or beige rather?].","authors":"Ilse Zündorf, Theo Dingermann","doi":"10.1002/pauz.201290099","DOIUrl":"https://doi.org/10.1002/pauz.201290099","url":null,"abstract":"","PeriodicalId":19878,"journal":{"name":"Pharmazie in Unserer Zeit","volume":"41 6","pages":"443-4"},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pauz.201290099","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31198230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：